Dopamine dependent decrease in enkephalin and substance P levels in basal ganglia regions of postmortem parkinsonian...

Area of Science:

• Neuroscience
• Biochemistry
• Pathology

Background:

• Parkinson's disease (PD) is characterized by significant dopamine (DA) depletion in the basal ganglia.
• Opioid (Met5-enkephalin, ME; dynorphin A (1-8), DYN) and tachykinin (substance P, SP) systems are implicated in motor and non-motor functions.
• The interplay between DA loss and these peptidergic systems in PD remains incompletely understood.

Purpose of the Study:

• To investigate the relationship between the extent of dopamine (DA) loss and alterations in Met5-enkephalin (ME), dynorphin A (DYN), and substance P (SP) levels.
• To examine these changes in postmortem brain tissue from Parkinson's disease (PD) patients, specifically in the basal ganglia and frontal cortex.
• To compare findings with experimental DA deficiency models in rodents.

Main Methods:

• Analysis of postmortem brain tissue (caudate, putamen, frontal cortex) from Parkinson's disease (PD) patients and controls.
• Quantification of dopamine (DA), 5-hydroxytryptamine (5-HT), Met5-enkephalin (ME), dynorphin A (DYN), and substance P (SP) using radioimmunoassays and HPLC with electrochemical detection.
• Classification of PD tissues based on the percentage of DA loss (less than 80% vs. greater than 80% compared to controls).

Main Results:

• A significant reduction in ME levels was observed in the caudate nucleus and SP levels in the putamen of PD patients with greater than 80% DA loss.
• No significant changes in DYN levels were detected in the basal ganglia, nor were any peptide level changes found in the frontal cortex.
• Experimental DA deficiency in rodents induced by 6-hydroxydopamine (6-OHDA) resulted in increased ME and decreased SP, contrasting with the lower levels found in postmortem PD basal ganglia.

Conclusions:

• The study suggests a secondary, dopamine (DA)-dependent depletion of enkephalin and tachykinin peptides in the basal ganglia of Parkinson's disease (PD) patients.
• These peptidergic system alterations may contribute to the diverse symptoms of PD, beyond motor deficits.
• Understanding these neurochemical changes is crucial for comprehending the broader pathophysiology and progression of Parkinson's disease.